{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:37:22Z","timestamp":1793745442636,"version":"4.6.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13757-1","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T06:53:31Z","timestamp":1741157611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis."],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3218-3150","authenticated-orcid":false,"given":"Made Agus Mahendra","family":"Inggas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0631-3570","authenticated-orcid":false,"given":"Utsav","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-2163","authenticated-orcid":false,"given":"Jeremiah Hilkiah","family":"Wijaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2646-5882","authenticated-orcid":false,"given":"Nina","family":"Otinashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyshnav Rajagopal","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4528-6717","authenticated-orcid":false,"given":"Abhay Krishnan","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-7337","authenticated-orcid":false,"given":"Tawfiq","family":"Turjman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6319-044X","authenticated-orcid":false,"given":"Surbhi","family":"Dadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4410-1512","authenticated-orcid":false,"given":"Mari","family":"Gadaevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1238-6537","authenticated-orcid":false,"given":"Azada","family":"Ismayilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7502-5597","authenticated-orcid":false,"given":"Shiva Jashwanth","family":"Gaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6977-7593","authenticated-orcid":false,"given":"Prakriti","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-3085","authenticated-orcid":false,"given":"Saurabh","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"13757_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/biomedicines7030069","volume":"7","author":"H Strobel","year":"2019","unstructured":"Strobel H, Baisch T, Fitzel R, et al. Temozolomide and other Alkylating agents in Glioblastoma Therapy. Biomedicines. 2019;7:69. https:\/\/doi.org\/10.3390\/biomedicines7030069.","journal-title":"Biomedicines"},{"key":"13757_CR2","doi-asserted-by":"publisher","unstructured":"Parisi S, Corsa P, Raguso A et al. (2015) Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review. Biomed Res Int 2015:620643. https:\/\/doi.org\/10.1155\/2015\/620643","DOI":"10.1155\/2015\/620643"},{"key":"13757_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.20517\/cdr.2020.79","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021;4:17\u201343. https:\/\/doi.org\/10.20517\/cdr.2020.79.","journal-title":"Cancer Drug Resist"},{"key":"13757_CR4","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.3390\/cancers15072116","volume":"15","author":"SSK Yalamarty","year":"2023","unstructured":"Yalamarty SSK, Filipczak N, Li X, et al. Mechanisms of resistance and current treatment options for Glioblastoma Multiforme (GBM). Cancers (Basel). 2023;15:2116. https:\/\/doi.org\/10.3390\/cancers15072116.","journal-title":"Cancers (Basel)"},{"key":"13757_CR5","doi-asserted-by":"publisher","first-page":"e0230492","DOI":"10.1371\/journal.pone.0230492","volume":"15","author":"SC Massey","year":"2020","unstructured":"Massey SC, White H, Whitmire P, et al. Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma. PLoS ONE. 2020;15:e0230492. https:\/\/doi.org\/10.1371\/journal.pone.0230492.","journal-title":"PLoS ONE"},{"key":"13757_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/WNF.0000000000000458","volume":"44","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Wu J, Shi L. Adjuvant temozolomide for the treatment of Glioblastoma: a Meta-analysis of Randomized Controlled studies. Clin Neuropharm. 2021;44:132\u20137. https:\/\/doi.org\/10.1097\/WNF.0000000000000458.","journal-title":"Clin Neuropharm"},{"key":"13757_CR7","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"13757_CR8","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"13757_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5114\/ninp.2013.34398","volume":"47","author":"D Szczepanek","year":"2013","unstructured":"Szczepanek D, Marchel A, Moska\u0142a M, et al. Efficacy of concomitant and adjuvant temozolomide in glioblastoma treatment. A multicentre randomized study. Neurol Neurochir Pol. 2013;47:101\u20138. https:\/\/doi.org\/10.5114\/ninp.2013.34398.","journal-title":"Neurol Neurochir Pol"},{"key":"13757_CR10","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ, et al. Short-course Radiation plus Temozolomide in Elderly patients with Glioblastoma. N Engl J Med. 2017;376:1027\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1611977.","journal-title":"N Engl J Med"},{"key":"13757_CR11","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1200\/JCO.2005.00.331","volume":"23","author":"H Athanassiou","year":"2005","unstructured":"Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23:2372\u20137. https:\/\/doi.org\/10.1200\/JCO.2005.00.331.","journal-title":"J Clin Oncol"},{"key":"13757_CR12","doi-asserted-by":"publisher","first-page":"6767","DOI":"10.1158\/1078-0432.CCR-05-0722","volume":"11","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11:6767\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0722.","journal-title":"Clin Cancer Res"},{"key":"13757_CR13","first-page":"133","volume":"16","author":"D Karacetin","year":"2011","unstructured":"Karacetin D, Okten B, Yalcin B, Incekara O. Concomitant temozolomide and radiotherapy versus radiotherapy alone for treatment of newly diagnosed glioblastoma multiforme. J BUON. 2011;16:133\u20137.","journal-title":"J BUON"},{"key":"13757_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7.","journal-title":"Lancet Oncol"},{"key":"13757_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s00066-008-1897-0","volume":"184","author":"M Kocher","year":"2008","unstructured":"Kocher M, Frommolt P, Borberg SK, et al. Randomized study of postoperative Radiotherapy and Simultaneous Temozolomide without Adjuvant Chemotherapy for Glioblastoma. Strahlenther Onkol. 2008;184:572\u20139. https:\/\/doi.org\/10.1007\/s00066-008-1897-0.","journal-title":"Strahlenther Onkol"},{"key":"13757_CR16","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/curroncol31070296","volume":"31","author":"M Jezierza\u0144ski","year":"2024","unstructured":"Jezierza\u0144ski M, Nafalska N, Stopyra M, et al. Temozolomide (TMZ) in the treatment of Glioblastoma Multiforme\u2014A Literature Review and Clinical outcomes. Curr Oncol. 2024;31:3994\u20134002. https:\/\/doi.org\/10.3390\/curroncol31070296.","journal-title":"Curr Oncol"},{"key":"13757_CR17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med. 2005;352:987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"key":"13757_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11060-008-9530-8","volume":"88","author":"DJ Sher","year":"2008","unstructured":"Sher DJ, Henson JW, Avutu B, et al. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol. 2008;88:43\u201350. https:\/\/doi.org\/10.1007\/s11060-008-9530-8.","journal-title":"J Neurooncol"},{"key":"13757_CR19","doi-asserted-by":"publisher","first-page":"e74242","DOI":"10.1371\/journal.pone.0074242","volume":"8","author":"A Yin","year":"2013","unstructured":"Yin A, Zhang L, Cheng J, et al. Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: a Meta-analysis. PLoS ONE. 2013;8:e74242. https:\/\/doi.org\/10.1371\/journal.pone.0074242.","journal-title":"PLoS ONE"},{"key":"13757_CR20","doi-asserted-by":"publisher","first-page":"102532","DOI":"10.1016\/j.mex.2023.102532","volume":"12","author":"S Mancin","year":"2024","unstructured":"Mancin S, Sguanci M, Andreoli D, et al. Systematic review of clinical practice guidelines and systematic reviews: a method for conducting comprehensive analysis. MethodsX. 2024;12:102532. https:\/\/doi.org\/10.1016\/j.mex.2023.102532.","journal-title":"MethodsX"},{"key":"13757_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0741932518813142","volume":"41","author":"S King","year":"2020","unstructured":"King S, Davidson K, Chitiyo A, Apple D. Evaluating article search and selection procedures in Special Education Literature Reviews. Remedial Special Educ. 2020;41:3\u201317. https:\/\/doi.org\/10.1177\/0741932518813142.","journal-title":"Remedial Special Educ"},{"key":"13757_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/sim.1023","volume":"21","author":"JA Berlin","year":"2002","unstructured":"Berlin JA, Santanna J, Schmid CH, et al. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med. 2002;21:371\u201387. https:\/\/doi.org\/10.1002\/sim.1023.","journal-title":"Stat Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13757-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13757-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13757-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T06:53:33Z","timestamp":1741157613000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13757-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13757"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13757-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"31 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"399"}}